Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Relapsed or Refractory Multiple Myeloma (MM)”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Early research (Phase 1)Looking for participantsNCT06799026
What this trial is testing

Vaccination With Dendritic Cell (DC)/Multiple Myeloma (MM) Fusions in Combination With Elranatamab in Relapsed or Refractory Multiple Myeloma

Who this might be right for
Multiple MyelomaRelapse Multiple MyelomaRefractory Multiple Myeloma
David Avigan 25
Early research (Phase 1)Ended earlyNCT04887259
What this trial is testing

Trial of LAVA-051 in Patients with Relapsed/refractory CLL, MM, or AML

Who this might be right for
Chronic Lymphocytic LeukemiaMultiple MyelomaAcute Myeloid Leukemia
Lava Therapeutics 16
Not applicableLooking for participantsNCT06515262
What this trial is testing

Safety and Efficacy of Anti-BCMA-GPRC5D CAR-T Cells Therapy in the Treatment of r/r MM

Who this might be right for
Relapsed/Refractory Multiple Myeloma
920th Hospital of Joint Logistics Support Force of People's Liberation Army of China 10
Testing effectiveness (Phase 2)Ended earlyNCT00499239
What this trial is testing

A Trial of GS-9219 in Chronic Lymphocytic Leukemia (CLL), Non-Hodgkin's Lymphoma (NHL) or Multiple Myeloma (MM)

Who this might be right for
Non-Hodgkin's LymphomaChronic Lymphocytic LeukemiaMultiple Myeloma
Gilead Sciences 32
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07107204
What this trial is testing

A Clinical Study of BT02 in Patients With Relapsed or Refractory Hematologic Malignancies

Who this might be right for
Relapsed or Refractory Hematologic MalignanciesLeukemiaLymphoma+1 more
Biotroy Therapeutics 116
Testing effectiveness (Phase 2)Looking for participantsNCT04988555
What this trial is testing

Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)

Who this might be right for
Leukemia, Myeloid, AcuteLeukemia, Lymphocytic, AcuteMultiple Myeloma+1 more
Sumitomo Pharma America, Inc. 606
Early research (Phase 1)Not Yet RecruitingNCT07725406
What this trial is testing

Low-Dose TBI Plus CAR T-Cell Therapy for Relapsed/Refractory DLBCL and Multiple Myeloma

Who this might be right for
Relapsed or Refractory Diffuse Large B Cell Lymphoma (DLBCL)Relapsed or Refractory Multiple Myeloma (MM)
Weill Medical College of Cornell University 32
Early research (Phase 1)UnknownNCT05438394
What this trial is testing

Clinical Study of Safety and Tolerability of Melphalan Hydrochloride for R/R MM

Who this might be right for
Multiple Myeloma
Peking University People's Hospital 24
Testing effectiveness (Phase 2)Looking for participantsNCT05972135
What this trial is testing

Outpatient Administration of Teclistamab or Talquetamab for Multiple Myeloma

Who this might be right for
Multiple Myeloma
SCRI Development Innovations, LLC 100
Not applicableLooking for participantsNCT06961669
What this trial is testing

Intravenous Autologous CD19 CAR-T Cells for R/ R MM, B-ALL, and B-Cell Lymphoma

Who this might be right for
Lymphoblastic LeukemiaRelapsed or Refractory Multiple Myeloma (RRMM)
Anhui Provincial Hospital 18
Early research (Phase 1)UnknownNCT05020639
What this trial is testing

TQB3820 in Patients With Hematological Malignancies

Who this might be right for
Hematological Malignancies
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. 116
Early research (Phase 1)Looking for participantsNCT05927571
What this trial is testing

A Study Evaluating the Safety, Pharmacokinetics, and Activity of the Combination of Cevostamab and Elranatamab in Participants With Relapsed or Refractory Multiple Myeloma (R/R MM)

Who this might be right for
Relapsed or Refractory Multiple Myeloma
Genentech, Inc. 120
Early research (Phase 1)Study completedNCT03275103
What this trial is testing

Dose-Escalation Study of Cevostamab in Participants With Relapsed or Refractory Multiple Myeloma (R/R MM)

Who this might be right for
Multiple Myeloma
Genentech, Inc. 355
Early research (Phase 1)Study completedNCT01575925
What this trial is testing

Study of Pomalidomide to Evaluate the Pharmacokinetics and Safety for Patients With Multiple Myeloma and Impaired Renal Function (POM Renal)

Who this might be right for
Multiple MyelomaRenal Impairment
Celgene 25
Testing effectiveness (Phase 2)Looking for participantsNCT06645678
What this trial is testing

Mezigdomide and Elranatamab for Relapsed and/or Refractory Multiple Myeloma

Who this might be right for
Relapsed Refractory Multiple Myeloma (RRMM)
YOUNGIL KOH 75
Early research (Phase 1)Study completedNCT00258245
What this trial is testing

Arsenic Trioxide and Ascorbic Acid Combined With Bortezomib, Thalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma or Plasma Cell Leukemia

Who this might be right for
Multiple Myeloma and Plasma Cell Neoplasm
Barbara Ann Karmanos Cancer Institute 5
Large-scale testing (Phase 3)Not Yet RecruitingNCT07181239
What this trial is testing

Study of CM336 in Relapsed or Refractory Multiple Myeloma Patients

Who this might be right for
Multiple Myeloma (MM)
Keymed Biosciences Co.Ltd 280
Testing effectiveness (Phase 2)Study completedNCT01526694
What this trial is testing

Phase II Trial Designed to Determine Efficacy and Safety of Bendamustine+Dexamethasone+Thalidomide in R/R MM

Who this might be right for
Multiple Myeloma
Azienda Ospedaliera di Bolzano 30
Not applicableNot Yet RecruitingNCT07015021
What this trial is testing

The Efficacy and Safety of the Combination Therapy of Daratumumab, Cabozantinib, Pomalidomide, and Dexamethasone (D-KPd) in the Treatment of High-risk First-time Relapsed or Primary Refractory MM Patients

Who this might be right for
Multiple MyelomaCarfilzomibDaratumumab+1 more
The First Affiliated Hospital of Soochow University 72
Testing effectiveness (Phase 2)Active Not RecruitingNCT02899052
What this trial is testing

Study of Venetoclax in Combination With Carfilzomib and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma (MM)

Who this might be right for
Multiple Myeloma
AbbVie 120
Next Page